News | November 29, 2007

Study Sides with CADStream for Evaluation of Kinetics in Breast MRI

November 30, 2007 – Confirma announced that a study presented at RSNA found that the CADstream system’s patented “worst curve” algorithm for analyzing kinetics may assist in determining malignancy, concluding that any washout enhancement was associated with malignancy in nearly half of lesions.

The study, by the Seattle Cancer Care Alliance and the University of Washington, led by Dr. Lilian Wang, focused on the evaluation of kinetics and found that the most suspicious curve as identified by CADstream was significantly different between benign and malignant lesions. These findings support the recommendation of the American College of Radiology’s Breast Imaging Reporting and Database System (BI-RADS) Atlas for breast MRI to report the “worst looking” curve.

Entitled MRI Detected Suspicious Breast Findings: Comparison of Kinetic Features Measured by Computer-aided Evaluation in Benign and Malignant Lesion, the study examined 125 suspicious lesions (42 malignant, 83 benign) for which computer-aided-evaluation (CADstream) and subsequent image guided biopsy had been performed, out of a pool of 1538 breast MRI examinations conducted from November 2004 to November 2006.

The study compared three distinct computer-aided-evaluation kinetic features of suspicious breast MRI lesions to identify which may best predict benign or malignant outcomes, concluding that of the kinetic features analyzed only the most suspicious curve type as identified by CADstream was significantly different between benign and malignant lesions.

The CADstream system automates analysis, reporting and interventional planning of studies and promotes standardization with the incorporation of the American College of Radiology’s Breast Imaging Reporting and Database System (BI-RADS), which guides the breast cancer diagnostic routine and decision-making process. Confirma’s next-generation version of CADstream for breast MRI, launched this week at the RSNA meeting, includes a new customizable BI-RADS-centric user interface that accommodates a variety of user experience levels. Other CADstream enhancements include improved 3D renderings and tools for morphology reporting.

For more information: www.confirma.com

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...